FIRE Funds Income Target ETF FIRI 深 沪
等待开盘 10-24 09:30:00 美东时间
18.94
+0.020
+0.11%
华盛通- 最 高18.94
- 今 开18.87
- 成交量 599股
- 最 低 18.87
- 昨 收 18.92
- 总市值 123.11万
- 52周最高 19.115
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 17.6612
- 委 比 0.00%
- 总股本 6.50万
- 历史最高 18.94
- 量 比 0.06
- 振 幅 0.37%
- 历史最低 17.7417
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inhibrx Biosciences To Webcast ChonDRAgon Study Results For Ozekibart In Chondrosarcoma On October 23
– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical
10-23 04:02
Merus Reports Interim Phase 2 Results for Petosemtamab in Metastatic Colorectal Cancer
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and
10-14 19:34
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
09-29 20:19
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-16 19:00
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Break...
09-08 21:30
Oncolytics Biotech Reports Pelareorep Boosts Survival In Colorectal Cancer Patients
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today highlighted clinical and translational data from three metastatic
09-08 19:10
AIM ImmunoTech Announces Company Update Including Mid-Year Report Of Ampligen In Combination With AstraZeneca's Imfinzi For Treatment Of Pancreatic Cancer Demonstrating Signs Of Both No Significant Toxicity And Superior PFS And OS.Company Also Bolstered Cash Position To Fund Operations For ~12 Months
Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both
08-04 21:06
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
07-28 23:12
AIM ImmunoTech Announces Mid-Year Data From Phase 2 DURIPANC Trial Of Ampligen And AstraZeneca's Imfinzi In Metastatic Pancreatic Cancer Patients Post-FOLFIRINOX
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
07-28 21:03
